ADVERTISEMENT
Poster
CIO 2020-22
CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2
R. Lencioni, J. Knox, A.-L. Cheng, S. Cleary, P. Galle, N. Kokudo, J.-W. Park, J. Zhou, P. He, S. Morgan, G. Cohen, J. Fan